Enabling Early Stage Muscle Drug Discovery with MyoScreen™, a High-throughput High-content Phenotypic Screening Platform Deploying Micropatterned Human Primary Skeletal Myotubes
Joanne Young,
Senior Scientist,
Cytoo SA
CYTOO has recently developed a disease relevant phenotypic muscle drug
discovery platform to fully leverage the characterization of compounds
at an early stage of the drug discovery pipeline. MyoScreen™ deploys
imaging and image-analysis methodology along with a micropatterned plate
system that allows the precise control of myotube length and the
formation of highly aligned myotubes.
In this seminar, I will discuss
the robust performance of the MyoScreen™ platform and show how it
exploits the improved architecture and maturity of micropatterned
myotubes, which are superior to standard 2D culture, to quantitatively
analyze drug effects on proliferation, hypertrophy/atrophy,
acetylcholine receptors, as well as providing a screening index of
contractile force. I will also describe actual use of MyoScreen™ in a
primary screen with secondary hit validation, focusing on two intriguing
hits that were identified to enhance myotube function by distinct
mechanisms of action.
|
|
